Heart Failure

The AJMC^® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.

Latest News

Carpal tunnel syndrome may prove to be a potential indicator for cardiac amyloidosis. | Image Credit: bluebay2014-stock.adobe.com

Carpal Tunnel Syndrome Linked to Cardiac Amyloidosis

By Sabrina McCrear

July 17th 2025

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of early diagnosis for better heart failure outcomes.

The approval was based on results from the phase 3 FINEARTS-HF trial. | Image Credit: aznan - stock.adobe.com

FDA Approves Finerenone for Heart Failure With Mildly Reduced or Preserved LVEF

By Rose McNulty

July 14th 2025

Dallas Texas | Image Credit: © SeanPavonePhoto - stock.adobe.com

Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most

By Christina Mattina

March 13th 2025

Phoenix Arizona | Image Credit: © Kevin Ruck - stock.adobe.com

Closing the Gaps in Cardiac Care With Technology, Collaboration

By Christina Mattina

March 12th 2025

the top 5 heart failure content of 2024

Top 5 Most-Read Heart Failure Articles of 2024

By Hayden E. Klein

December 23rd 2024

Continuing Medical Education

July 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 17th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

July 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

July 17th 2025

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology

July 17th 2025

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Cardiology, Rare Diseases

July 17th 2025

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

More News

Are Prognostic Models Accurate at Predicting Mortality, Morbidity in Patients With Chronic Heart Failure?

February 8th 2020

Are Prognostic Models Accurate at Predicting Mortality, Morbidity in Patients With Chronic Heart Failure?

In 2017, heart failure contributed to 1 in 8 deaths. This inability of the heart to function at its optimal level led to an estimated $30.7 billion in annual healthcare costs in 2012, including healthcare services, medicines, and missed work.

Deeper Dive Into Rosiglitazone Data Reveals Link to CV Risk, Especially Heart Failure

February 6th 2020

Deeper Dive Into Rosiglitazone Data Reveals Link to CV Risk, Especially Heart Failure

The most detailed look ever at data for rosiglitazone, the diabetes drug marketed by GlaxoSmithKline (GSK) as Avandia, shows the one-time blockbuster significantly raises the overall risk of heart problems or cardiovascular death, calling attention to the need for more transparency in data collection.

Dr Javed Butler: Recognizing Risk of Heart Failure in Patients With Diabetes Key to Preventive Care

February 1st 2020

Dr Javed Butler: Recognizing Risk of Heart Failure in Patients With Diabetes Key to Preventive Care

Improving recognition of the link between heart failure and diabetes can promote preventive care for at-risk patients, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.

Shock Only or Drug-Shock? 2 Different Cardioversion Techniques Equally Effective, Study Says

January 31st 2020

Shock Only or Drug-Shock? 2 Different Cardioversion Techniques Equally Effective, Study Says

Allison Inserro

The drug-shock strategy was more effective for patients experiencing atrial fibrillation for the first time and for patients younger than 70 years, the researchers said.

Are Transitional Care Services Worth Investing In for Heart Failure?

January 28th 2020

Are Transitional Care Services Worth Investing In for Heart Failure?

Heart failure (HF) taxes the American healthcare system by a total of $39.2 billion to $60 billion each year. This amount is expected to increase up to 20% by 2030 and total $70 billion. Worldwide, HF has been diagnosed in 26 million individuals, and this number is rising.

Experiments Give Insights Into Dapagliflozin's Cardioprotective Effects

January 25th 2020

Experiments Give Insights Into Dapagliflozin's Cardioprotective Effects

The authors write that the drug's apparent cardioprotective effects in the angiotensin II stressed mice—the decreased fibrosis, reduced inflammation and oxidative stress—all merit further study.

Does Excess Body Weight Equal Adverse Heart Health Outcomes?

January 20th 2020

Does Excess Body Weight Equal Adverse Heart Health Outcomes?

Hypertrophic cardiomyopathy is an abnormal thickening of the heart muscle, with causes that include genetic mutations and myofiber disarray (an abnormal heart muscle cell arrangement). Individuals who have this condition are prone to obesity (body mass index, 25 to

Dr Javed Butler on Importance of Diabetes Can Break Your Heart Initiative for American Heart Month

January 19th 2020

Dr Javed Butler on Importance of Diabetes Can Break Your Heart Initiative for American Heart Month

Diabetes Can Break Your Heart is an important initiative that highlights the vital need for heightened education on the link between diabetes and heart failure, especially with American Heart Month looming, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.

What We're Reading: Improvements in Health Disparities Stall; Reanimating Hearts; Aging Population Concerns

January 16th 2020

What We're Reading: Improvements in Health Disparities Stall; Reanimating Hearts; Aging Population Concerns

Since 2016, racial and ethnic healthcare disparities have not improved; a new method of "reanimating" hearts from recently deceased donors for transplants is being tested; the new decade prompts concerns about an aging population.

Risk of Heart Disease Among Childhood Cancer Survivors Falls Since 1970s, Data Show

January 16th 2020

Risk of Heart Disease Among Childhood Cancer Survivors Falls Since 1970s, Data Show

While the number of survivors who had cardiotoxic treatments increased, the doses they received decreased. Radiation exposure fell from 77% in the 1970s to 40% in the 1990s.

Suggested Link Between Regional Heart Failure Treatment Gaps, Patient Outcomes

January 15th 2020

Suggested Link Between Regional Heart Failure Treatment Gaps, Patient Outcomes

The median time to first intravenous therapy for acute heart failure (AHF) is 3.0 hours in North America compared with 1.2 hours in all other regions, in the International Registry to Assess Medical Practice with Longitudinal Observation for Treatment of Heart Failure. Treatment timing and differences may affect outcomes in patients with AHF.

Dr Javed Butler Discusses Why People With Diabetes Are at Greater Risk of Heart Failure

January 11th 2020

Dr Javed Butler Discusses Why People With Diabetes Are at Greater Risk of Heart Failure

There are multiple ways in which people with diabetes can develop heart failure, which is why heightened awareness through the initiative Diabetes Can Break Your Heart is warranted, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.

Patients Hospitalized for Heart Failure Have 11 Times the Risk of Kidney Failure

January 10th 2020

Patients Hospitalized for Heart Failure Have 11 Times the Risk of Kidney Failure

Hospitalizations due to heart failure (HF) were associated with a risk for kidney failure (KF) that was 11.4-times greater compared with patients who did not have cardiovascular disease (CVD). Among a group of CVDs that also included atrial fibrillation, coronary heart disease, and stroke, HF was associated with the highest risk of developing subsequent KF.

FDA Grants Dapagliflozin Priority Review for Heart Failure, Even for Those Without Diabetes

January 9th 2020

FDA Grants Dapagliflozin Priority Review for Heart Failure, Even for Those Without Diabetes

Priority review was based on phase 3 results from DAPA-HF, presented in Paris at the European Society of Cardiology and published in the New England Journal of Medicine.

Timing, Accessibility of Resources Key to Effective Treatment of Fulminant Myocarditis

January 7th 2020

Timing, Accessibility of Resources Key to Effective Treatment of Fulminant Myocarditis

Matthew Gavidia

In a statement published today by he American Heart Association, researchers provide key resources needed to diagnose and treat fulminant myocarditis successfully.

The Great Revascularization Strategy Debate: Coronary Artery Bypass Graft or Percutaneous Coronary Intervention?

December 30th 2019

The Great Revascularization Strategy Debate: Coronary Artery Bypass Graft or Percutaneous Coronary Intervention?

Patients with acute heart failure often require immediate treatment to restore optimal heart function. The 2 primary methods of revascularization are coronary artery bypass graft and percutaneous coronary intervention, but the preferred strategy for use in these patients requires clarification due to risk.

Socioeconomic Status Tied to Risk of Chronic Disease, Including Cardiac, Diabetes

December 21st 2019

Socioeconomic Status Tied to Risk of Chronic Disease, Including Cardiac, Diabetes

Sara Karlovitch

Social inequalities are created before the onset of the illness, rather than after it, according to researchers.

Healthcare, Genetic Testing Disparities Persist in Black Patients With Hypertrophic Cardiomyopathy

December 19th 2019

Healthcare, Genetic Testing Disparities Persist in Black Patients With Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is an inherited condition in which mutations in genes that encode the sarcomere proteins in the heart cause an abnormal thickening of that muscle, with no known cure. In black patients, HCM is usually diagnosed at a younger age and accompanied by a greater burden of symptomatic heart failure. These patients, however, are not well represented in surveys of the condition, which tend to focus on white patients.

Is There a Future for CAR T-Cell Therapy in Heart Failure?

December 13th 2019

Is There a Future for CAR T-Cell Therapy in Heart Failure?

Chimeric antigen receptor (CAR) T cells are lymphocytes genetically engineered to recognize and bind to specific proteins on cancer cells. Studies are currently underway for applications in other fields.

Trial Data Suggest Beta Blockers Not Best Choice in Heart Failure With Preserved Ejection Fraction

December 13th 2019

Trial Data Suggest Beta Blockers Not Best Choice in Heart Failure With Preserved Ejection Fraction

The results are sure to generate interest as heart failure with preserved ejection fraction lacks treatment options, but that could change as results are expected in outcomes trials that are studying sodium glucose co-transporter 2 inhibitors in heart failure, both with preserved and reduced ejection fraction.

Dr John McMurray Details the Preliminary Cost-Effectiveness Distinction of Dapagliflozin

December 7th 2019

Dr John McMurray Details the Preliminary Cost-Effectiveness Distinction of Dapagliflozin

Cost-effectiveness analyses have not been conducted on the DAPA-HF trial as of yet, but in healthcare systems in which dapagliflozin is not particularly expensive, results are likely to be favorable, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.

Want a Low-Cost Way to Prevent Heart Failure? Brush Your Teeth, Study Suggests

December 3rd 2019

Want a Low-Cost Way to Prevent Heart Failure? Brush Your Teeth, Study Suggests

Although the study did not pinpoint the exact mechanism behind the link, the authors wrote that the presence of plaque below the gumline can allow oral bacteria to reach the circulatory system. Certain bacteria that reach the gut can trigger inflammation.

Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure

November 30th 2019

Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure

Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.

Number of Cardiovascular Deaths Rising Among Cancer Survivors, Study Finds

November 26th 2019

Number of Cardiovascular Deaths Rising Among Cancer Survivors, Study Finds

A new study says that more than 1 in 10 of the 17 million cancer survivors in the United States will die from cardiovascular disease (CVD).

Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Patients With and Without Diabetes

November 23rd 2019

Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Patients With and Without Diabetes

In patients with heart failure, both with and without diabetes, dapagliflozin was shown to provide identical efficacy and possibly beneficial effects on the heart, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.

This Week in Managed Care: November 22, 2019

November 22nd 2019

This Week in Managed Care: November 22, 2019

This week, the top managed care news included research that shows stents may offer no more value than drugs for some heart patients; a ban on flavored tobacco products gains momentum; a survey finds most American families struggle with social factors that impact health.

Neurohormonal Blockade, Left Ventricular Assist Devices Equal Improved Survival Outcomes in Patients With Heart Failure

November 22nd 2019

Neurohormonal Blockade, Left Ventricular Assist Devices Equal Improved Survival Outcomes in Patients With Heart Failure

Quality of life and 6-minute walk test also improve with this treatment combination.

AstraZeneca Initiative to Highlight Link Between Diabetes, Heart Failure

November 15th 2019

AstraZeneca Initiative to Highlight Link Between Diabetes, Heart Failure

Called Diabetes Can Break Your Heart, the initiative seeks to get doctors and patients talking about the connection between diabetes and heart failure, so that symptoms are not missed and treatment that could prevent heart failure occurs early. A Diabetes Heartbreaker tour, which will feature a virtual reality experience with immersive technology, will kick off this weekend at the American Heart Association Scientific Sessions in Philadelphia.

Mavacamten Has Positive Impact on Cardiac Structure in Certain Cases of Cardiomyopathy, Data Show

November 11th 2019

Mavacamten Has Positive Impact on Cardiac Structure in Certain Cases of Cardiomyopathy, Data Show

Hypertrophic cardiomyopathy is often an inherited condition and patients may not show symptoms, or those symptoms may be vague, such as fatigue or shortness of breath. The condition can cause varied levels of risk and can result in sudden cardiac death.

Kaiser Permanente Study Results Suggest Link Between Older Age, Heart Failure

November 6th 2019

Kaiser Permanente Study Results Suggest Link Between Older Age, Heart Failure

The rate of decrease in deaths from heart disease (HD) slowed between 2011 and 2014 versus 2000 and 2011, while the population above 65 years jumped 22.9% and there was a concurrent 38% rise in deaths from HD among this patient population.

...

11 12 13 14 15 16 17 18 19

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions